Clinical Trial

A Platform Study of In Vivo CAR-T for Treating Advanced Malignant Tumors Based on Target Screening

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-arm, open-label, single-center, dose-escalation Phase I platform study designed to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics, and pharmacodynamics of an in vivo CAR-T therapy (V001 Injection, targeting BCMA, GPRC5D, DLL3,FcRH5, etc.) in patients with advanced malignant tumors.
Protocol Amendment History 1 change
minor Trial arms changed: 3 -> 4 2026-05-14
Trial Details
NCT Number NCT07395479
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions Advanced Malignant Tumours
Enrollment 50 participants
Start Date 2025-11-21
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-13